temozolomide has been researched along with B-Cell Lymphoma in 8 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Temozolomide chemotherapy has become part of the therapy used to treat glioblastoma multiforme and refractory anaplastic astrocytoma." | 4.86 | Emergence of cytomegalovirus disease in patients receiving temozolomide: report of two cases and literature review. ( Aguado, JM; García-Reyne, A; Juan, RS; Lalueza, A; Lizasoain, M; López-Medrano, F; Martínez, P; Meije, Y; Rodríguez, V, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zakaria, Z | 1 |
| Fenton, E | 1 |
| Khalil, A | 1 |
| Sattar, MT | 1 |
| Molnar, P | 1 |
| Meije, Y | 1 |
| Lizasoain, M | 1 |
| García-Reyne, A | 1 |
| Martínez, P | 1 |
| Rodríguez, V | 1 |
| López-Medrano, F | 1 |
| Juan, RS | 1 |
| Lalueza, A | 1 |
| Aguado, JM | 1 |
| Adachi, J | 1 |
| Mishima, K | 1 |
| Wakiya, K | 1 |
| Suzuki, T | 1 |
| Fukuoka, K | 1 |
| Yanagisawa, T | 1 |
| Matsutani, M | 1 |
| Sasaki, A | 1 |
| Nishikawa, R | 1 |
| Lerro, KA | 1 |
| Lacy, J | 1 |
| Enting, RH | 1 |
| Demopoulos, A | 1 |
| DeAngelis, LM | 1 |
| Abrey, LE | 1 |
| Herrlinger, U | 1 |
| Hebart, H | 1 |
| Kanz, L | 1 |
| Dichgans, J | 1 |
| Weller, M | 1 |
| Makino, K | 1 |
| Nakamura, H | 1 |
| Kudo, M | 1 |
| Takeshima, H | 1 |
| Kuratsu, J | 1 |
| Reni, M | 1 |
| Ferreri, AJ | 1 |
| Landoni, C | 1 |
| Villa, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma[NCT01235793] | Phase 2 | 11 participants (Actual) | Interventional | 2010-10-14 | Terminated (stopped due to The clinical trial was terminated due to poor enrollment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide. (NCT01235793)
Timeframe: One Year
| Intervention | dose in mg/m^2 (Number) |
|---|---|
| DRBEAT Regimen | 773.25 |
"Efficacy of the DRBEAT Regimen will be assessed by analysis of~one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression*, or death, (*Progression is defined as meeting the response criteria listed in Table 4: Response Criteria for Primary Central Nervous System Lymphoma according to Abrey LE, Batchelor TT, Ferreri AJM et al.)~and~Overall survival, defined as the time interval between the date of transplant and the date of death from any cause." (NCT01235793)
Timeframe: (1) One Year (2) Until date of death from any cause, assessed up to 2 years
| Intervention | Days (Median) | |
|---|---|---|
| Progression Free Survival | Overall Survival | |
| DRBEAT Regimen | 132 | 564 |
2 reviews available for temozolomide and B-Cell Lymphoma
| Article | Year |
|---|---|
Emergence of cytomegalovirus disease in patients receiving temozolomide: report of two cases and literature review.
Topics: Aged; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Cytomegalovirus Infection | 2010 |
Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antigens, Neop | 2004 |
6 other studies available for temozolomide and B-Cell Lymphoma
| Article | Year |
|---|---|
Stupp-treated glioblastoma accompanied by EBV-positive primary CNS lymphoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Clinical Protocols; Dac | 2014 |
O⁶-methylguanine-DNA methyltransferase promoter methylation in 45 primary central nervous system lymphomas: quantitative assessment of methylation and response to temozolomide treatment.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarb | 2012 |
Case report: a patient with primary CNS lymphoma treated with temozolomide to complete response.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; | 2002 |
Relapse of primary CNS lymphoma after more than 10 years in complete remission.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Mo | 2005 |
Complete response to temozolomide treatment in an elderly patient with recurrent primary central nervous system lymphoma--case report.
Topics: Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Humans; | 2007 |
Salvage therapy with temozolomide in an immunocompetent patient with primary brain lymphoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Immunocompetence; Lym | 2000 |